China Looks To Amend Drug Registration Regulation With Bolar Exemption That Favors Generics
This article was originally published in PharmAsia News
Executive Summary
China FDA released a draft regulation on drug registration that formalizes the “Bolar Exemption,” but the approach taken is unbalanced, according to experts, and would end up favoring generic competitors.